Arterial Hypertension and Mesenchymal stem/stromal cells (MSC): what the trial registry contains
The ClinicalTrials.gov registry holds 11 records for MSC in Arterial Hypertension: 2 recruiting now, 0 labelled Phase 3 or 4, across 8 countries. Snapshot 2026-08-29.
Why this is studied in Arterial Hypertension
Resistant hypertension is a plumbing-and-signalling problem: vascular stiffness, renal sodium handling and sympathetic tone. Cell approaches are studied mostly for endothelial repair and inflammation, usually as an add-on to drugs rather than a replacement. Blood pressure is also the most placebo-responsive vital sign in medicine, which shapes how these trials must be designed.
What MSC means in this table
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
The numbers
Every figure below comes from one reproducible query (hypertension x mesenchymal stem cell) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 11 |
| Interventional studies in the sample | 9 |
| Recruiting right now | 2 |
| Completed | 6 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 or Phase 4 records | 0 |
| Countries with at least one site | 8 |
| Median planned enrolment | 51 participants |
| Largest single planned enrolment | 500 participants |
| First / most recent start year | 2012 — 2024 |
How mature is this evidence?
There is no confirmatory research programme here — 11 registrations, all early-phase or unlabelled, 2 of them active.
0 of these records (0%) were terminated, withdrawn or suspended, against 6 marked completed; unfinished studies rarely appear in marketing summaries.
| Phase label | Records | Share |
|---|---|---|
| Phase 1 | 7 | 50% |
| Not applicable | 4 | 29% |
| Phase 2 | 3 | 21% |
Median planned enrolment is 51 participants (largest single study: 500). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Research is not evenly spread: United States carries about 33% of the country mentions among 8 countries with sites.
| Country | Studies with a site there |
|---|---|
| United States | 4 |
| Colombia | 2 |
| Brazil | 1 |
| China | 1 |
| Austria | 1 |
| United Arab Emirates | 1 |
| Spain | 1 |
| Indonesia | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Among the top lead sponsors, 3 are universities or hospitals and 5 are companies, making this a commercial area.
- Mayo Clinic — 2 records
- MD Stem Cells — 2 records
- Fundación Neumologica Colombiana — 1 record
- Cairo University — 1 record
- University of Sao Paulo — 1 record
- Liaocheng People's Hospital — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07183384 — MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction | Phase 1, Phase 2 | Recruiting | 80 | Universitas Padjadjaran | 2024-07-01 |
| NCT03011541 — Stem Cell Ophthalmology Treatment Study II | n/a | Recruiting | 500 | MD Stem Cells | 2016-01 |
| NCT07542067 — Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmo | Phase 1, Phase 2 | Completed | 1 | Fundación Neumologica Colombiana | 2024-05-15 |
| NCT04055415 — Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension | Phase 1, Phase 2 | Unknown | 60 | Liaocheng People's Hospital | 2019-08-01 |
| NCT02443961 — Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies | Phase 1 | Completed | 10 | Fundacion para la Investigacion Biomedica del Hospital Unive | 2019-04-02 |
| NCT02330978 — Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma. | Phase 1 | Completed | 2 | University of Sao Paulo | 2014-01 |
| NCT02266394 — Hypoxia and Inflammatory Injury in Human Renovascular Hypertension | Phase 1 | Completed | 42 | Mayo Clinic | 2014-10-21 |
| NCT01840540 — MSC for Occlusive Disease of the Kidney | Phase 1 | Completed | 6 | Mayo Clinic | 2013-04 |
| NCT03562715 — microRNAs Role in Pre-eclampsia Diagnosis | n/a | Completed | 200 | Cairo University | 2016-11-28 |
| NCT01920867 — Stem Cell Ophthalmology Treatment Study | n/a | Unknown | 300 | MD Stem Cells | 2012-08 |
What this page does and does not tell you
A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many MSC studies for Arterial Hypertension are recruiting right now?
2 of 11 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is MSC an approved treatment for Arterial Hypertension?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 11 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on MSC for Arterial Hypertension?
0 of 11 records carry a Phase 3 or Phase 4 label and 6 are marked completed. Registrations run from 2012 to 2024.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Arterial Hypertension: cell-therapy evidence and registered trials
- How much does stem cell therapy for Arterial Hypertension cost? (2026)
- Arterial Hypertension stem cell therapy — your questions answered (2026)
- Arterial Hypertension: cell-therapy evidence by therapy class
- MSC vs exosomes for Arterial Hypertension: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.